Taipei Times
Date: May 30, 2020
By: Lin Hui-chin / Staff reporter, with CNA
A researcher holds samples of monoclonal antibodies that could potentially be used in drugs to combat COVID-19 in an undated photograph.
Photo courtesy of Linkou Chang Gung Memorial Hospital.
The team, led by Huang Kuan-ying (黃冠穎), a doctor in the Department of Pediatric Infectious Diseases at Chang Gung Memorial Hospital’s Linkou branch in New Taipei City, is comprised of researchers from the hospital, Chang Gung University, Academia Sinica and the Institute of Preventive Medicine at the National Defense Medical Center, as well as Oxford University in the UK.
The team on Thursday said that it examined antibody function through immunofluorescence assays, neutralization tests and plaque reduction neutralization tests.
Tests with strains from different clades, including strains from China, the US, Europe and Egypt, showed an equivalent neutralization effect of 90 to 98 percent, it said.
[FULL STORY]
